Published in AIDS on July 31, 2007
Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study. AIDS Res Hum Retroviruses (2010) 0.83
Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach. Medicine (Baltimore) (2015) 0.82
Role of tipranavir in treatment of patients with multidrug-resistant HIV. Ther Clin Risk Manag (2010) 0.75
Marginal structural models and causal inference in epidemiology. Epidemiology (2000) 33.54
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology (2000) 15.40
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
Deletion/substitution/addition algorithm in learning with applications in genomics. Stat Appl Genet Mol Biol (2004) 2.77
Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS (2003) 0.93
The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr (2004) 0.89
Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients. HIV Clin Trials (2005) 0.87
Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy. HIV Clin Trials (2003) 0.84
Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res (2003) 10.50
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One (2009) 8.37
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med (2009) 6.61
Rejoinder to Tan. Int J Biostat (2008) 6.21
Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res (2007) 5.95
Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis (2006) 5.90
Viral population estimation using pyrosequencing. PLoS Comput Biol (2008) 5.89
Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions. Cell Stem Cell (2008) 5.76
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med (2003) 4.57
The timing of cortical neurogenesis is encoded within lineages of individual progenitor cells. Nat Neurosci (2006) 4.49
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS (2007) 3.94
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med (2004) 3.92
Estimation of direct causal effects. Epidemiology (2006) 3.78
Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc Natl Acad Sci U S A (2006) 3.76
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer (2008) 3.43
Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis (2009) 3.39
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis (2007) 3.16
A highly prevalent and genetically diversified Picornaviridae genus in South Asian children. Proc Natl Acad Sci U S A (2008) 3.12
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis (2009) 3.08
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol (2003) 2.98
Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol (2013) 2.96
The 'obligate diploid' Candida albicans forms mating-competent haploids. Nature (2013) 2.93
Survival ensembles. Biostatistics (2005) 2.88
Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem (2010) 2.86
HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis (2005) 2.86
Adult SVZ lineage cells home to and leave the vascular niche via differential responses to SDF1/CXCR4 signaling. Cell Stem Cell (2010) 2.85
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene (2003) 2.82
Deletion/substitution/addition algorithm in learning with applications in genomics. Stat Appl Genet Mol Biol (2004) 2.77
Auditing as part of the terminology design life cycle. J Am Med Inform Assoc (2006) 2.73
Hgc1, a novel hypha-specific G1 cyclin-related protein regulates Candida albicans hyphal morphogenesis. EMBO J (2004) 2.72
Bacterial peptidoglycan triggers Candida albicans hyphal growth by directly activating the adenylyl cyclase Cyr1p. Cell Host Microbe (2008) 2.68
Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr (2006) 2.56
History-adjusted marginal structural models for estimating time-varying effect modification. Am J Epidemiol (2007) 2.56
The Genia Event and Protein Coreference tasks of the BioNLP Shared Task 2011. BMC Bioinformatics (2012) 2.45
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis (2005) 2.43
Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol (2004) 2.42
Calibrating the end-Permian mass extinction. Science (2011) 2.41
Multiple testing. Part I. Single-step procedures for control of general type I error rates. Stat Appl Genet Mol Biol (2004) 2.34
World Antimalarial Resistance Network (WARN) III: molecular markers for drug resistant malaria. Malar J (2007) 2.30
Diagnosing and responding to violations in the positivity assumption. Stat Methods Med Res (2010) 2.29
Global transcriptome analysis of the heat shock response of Shewanella oneidensis. J Bacteriol (2004) 2.28
A transitional endogenous lentivirus from the genome of a basal primate and implications for lentivirus evolution. Proc Natl Acad Sci U S A (2008) 2.28
Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS (2008) 2.25
Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res (2009) 2.25
The sedimentation sign for differential diagnosis of lumbar spinal stenosis. Spine (Phila Pa 1976) (2013) 2.24
Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain (2006) 2.22
HIV sequence databases. AIDS Rev (2003) 2.20
Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. Am J Physiol Cell Physiol (2008) 2.18
Analysis of error concentrations in SNOMED. AMIA Annu Symp Proc (2007) 2.18
Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity (2012) 2.18
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS (2005) 2.16
Why don't they listen? Adherence to recommendations of infectious disease consultations. Clin Infect Dis (2004) 2.13
Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet (2002) 2.09
Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS One (2007) 2.09
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
Multiple testing methods for ChIP-Chip high density oligonucleotide array data. J Comput Biol (2006) 2.08
Cyclin-dependent kinases control septin phosphorylation in Candida albicans hyphal development. Dev Cell (2007) 2.07
Empirical efficiency maximization: improved locally efficient covariate adjustment in randomized experiments and survival analysis. Int J Biostat (2008) 2.06
Counterfactual links to the proportion of treatment effect explained by a surrogate marker. Biometrics (2005) 1.98
Obesity hypoventilation syndrome: prevalence and predictors in patients with obstructive sleep apnea. Sleep Breath (2007) 1.98
Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res (2006) 1.97
Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. J Virol (2008) 1.96
A targeted maximum likelihood estimator of a causal effect on a bounded continuous outcome. Int J Biostat (2010) 1.89
Endocannabinoids facilitate the induction of LTP in the hippocampus. Nat Neurosci (2002) 1.84
MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc Res (2009) 1.83
Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology (2006) 1.83
Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother (2004) 1.82
Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology (2010) 1.81
Assessing the effectiveness of antiretroviral adherence interventions. Using marginal structural models to replicate the findings of randomized controlled trials. J Acquir Immune Defic Syndr (2006) 1.81
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr (2005) 1.80
HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis (2011) 1.80
The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance. Bioinformatics (2009) 1.80
Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology (2008) 1.79
HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput Biol (2007) 1.78
Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS (2003) 1.78
Using regression models to analyze randomized trials: asymptotically valid hypothesis tests despite incorrectly specified models. Biometrics (2009) 1.77
Secondhand smoke exposure, pulmonary function, and cardiovascular mortality. Ann Epidemiol (2007) 1.76
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr (2009) 1.73
Drug resistance mutations in HIV-1. Top HIV Med (2003) 1.72
DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res (2010) 1.71
HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs (2012) 1.70
Candida albicans Cyr1, Cap1 and G-actin form a sensor/effector apparatus for activating cAMP synthesis in hyphal growth. Mol Microbiol (2009) 1.68
Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays. J Acquir Immune Defic Syndr (2005) 1.68